COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey

Overview

Journal Vaccines (Basel)

Date 2021 Apr 30

PMID 33919586

Citations 24

Authors

Arnold Hagens

Ahmet Cagkan Inkaya

Kasirga Yildirak

Mesut Sancar

Jurjen van der Schans

Aylin Acar Sancar

Serhat Unal

Maarten Postma

Selen Yegenoglu

Affiliations

Soon will be listed here.

Abstract

As of March 2021, COVID-19 has claimed the lives of more than 2.7 million people worldwide. Vaccination has started in most countries around the world. In this study, we estimated the cost-effectiveness of strategies for COVID-19 vaccination for Turkey compared to a baseline in the absence of vaccination and imposed measures by using an enhanced SIRD (Susceptible, Infectious, Recovered, Death) model and various scenarios for the first year after vaccination. The results showed that vaccination is cost-effective from a health care perspective, with an incremental cost-effectiveness ratio (ICER) of 511 USD/QALY and 1045 USD/QALY if vaccine effectiveness on transmission is equal or reduced to only 50% of effectiveness on disease, respectively, at the 90% baseline effectiveness of the vaccine. From a societal perspective, cost savings were estimated for both scenarios. Other results further showed that the minimum required vaccine uptake to be cost-effective would be at least 30%. Sensitivity and scenario analyses, as well as the iso-ICER curves, showed that the results were quite robust and that major changes in cost-effectiveness outcomes cannot be expected. We can conclude that COVID-19 vaccination in Turkey is highly cost-effective or even cost-saving.

Citing Articles

Pharmacy practice and policy research in Türkiye: a systematic review of literature.

Gulpinar G, Pehlivanli A, Babaar Z J Pharm Policy Pract. 2024; 17(1):2385939.

PMID: 39139388 PMC: 11321099. DOI: 10.1080/20523211.2024.2385939.

Using a Dynamic Model to Estimate the Cost-Effectiveness of HPV Vaccination in Iran.

Hagens A, Sloof A, Janghorban R Vaccines (Basel). 2024; 12(4).

PMID: 38675821 PMC: 11054652. DOI: 10.3390/vaccines12040438.

Economic evaluation of vaccination against COVID-19: A systematic review.

Zeinab D, Shahin N, Fateme M, Saeed B Health Sci Rep. 2024; 7(2):e1871.

PMID: 38332928 PMC: 10850437. DOI: 10.1002/hsr2.1871.

Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.

Espinosa O, Mora L, Sanabria C, Ramos A, Rincon D, Bejarano V Syst Rev. 2024; 13(1):30.

PMID: 38229123 PMC: 10790449. DOI: 10.1186/s13643-023-02411-1.

Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.

Mar J, Ibarrondo O, Estadilla C, Stollenwerk N, Antonanzas F, Blasco-Aguado R Pharmacoeconomics. 2023; 42(2):219-229.

PMID: 37910377 PMC: 10810962. DOI: 10.1007/s40273-023-01326-y.

References

Prem K, Liu Y, Russell T, Kucharski A, Eggo R, Davies N . The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health. 2020; 5(5):e261-e270. PMC: 7158905. DOI: 10.1016/S2468-2667(20)30073-6. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Schaffer DeRoo S, Pudalov N, Fu L . Planning for a COVID-19 Vaccination Program. JAMA. 2020; 323(24):2458-2459. DOI: 10.1001/jama.2020.8711. View

Koopmanschap M, Rutten F . A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996; 10(5):460-6. DOI: 10.2165/00019053-199610050-00003. View

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C . The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020; 78:185-193. PMC: 7162753. DOI: 10.1016/j.ijsu.2020.04.018. View

Hall V, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A . COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 397(10286):1725-1735. PMC: 8064668. DOI: 10.1016/S0140-6736(21)00790-X. View

Le T, Andreadakis Z, Kumar A, Roman R, Tollefsen S, Saville M . The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5):305-306. DOI: 10.1038/d41573-020-00073-5. View

Prem K, Cook A, Jit M . Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput Biol. 2017; 13(9):e1005697. PMC: 5609774. DOI: 10.1371/journal.pcbi.1005697. View

10.

Logunov D, Dolzhikova I, Shcheblyakov D, Tukhvatulin A, Zubkova O, Dzharullaeva A . Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275):671-681. PMC: 7852454. DOI: 10.1016/S0140-6736(21)00234-8. View

11.

Shapiro M, Karim F, Muscioni G, Augustine A . Adaptive Susceptible-Infectious-Removed Model for Continuous Estimation of the COVID-19 Infection Rate and Reproduction Number in the United States: Modeling Study. J Med Internet Res. 2021; 23(4):e24389. PMC: 8030656. DOI: 10.2196/24389. View

12.

Peirlinck M, Linka K, Sahli Costabal F, Kuhl E . Outbreak dynamics of COVID-19 in China and the United States. Biomech Model Mechanobiol. 2020; 19(6):2179-2193. PMC: 7185268. DOI: 10.1007/s10237-020-01332-5. View

13.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

14.

Bollyky T, Gostin L, Hamburg M . The Equitable Distribution of COVID-19 Therapeutics and Vaccines. JAMA. 2020; 323(24):2462-2463. DOI: 10.1001/jama.2020.6641. View

15.

Makhoul M, Ayoub H, Chemaitelly H, Seedat S, Mumtaz G, Al-Omari S . Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. Vaccines (Basel). 2020; 8(4). PMC: 7712303. DOI: 10.3390/vaccines8040668. View

16.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

17.

Avorn J, Kesselheim A . Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency. JAMA. 2020; 324(13):1284-1285. DOI: 10.1001/jama.2020.17101. View

18.

Kohli M, Maschio M, Becker D, Weinstein M . The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021; 39(7):1157-1164. PMC: 7832653. DOI: 10.1016/j.vaccine.2020.12.078. View

19.

Boulware D, Pullen M, Bangdiwala A, Pastick K, Lofgren S, Okafor E . A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020; 383(6):517-525. PMC: 7289276. DOI: 10.1056/NEJMoa2016638. View

20.

Salali G, Uysal M . COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. Psychol Med. 2020; :1-3. PMC: 7609204. DOI: 10.1017/S0033291720004067. View